Piper Jaffray has downgraded Trovagene (NYSE:TROV) from Neutral to Underweight in a report released on 03/16/2017.
Previously on Wednesday February 03, 2016, Maxim Group reported about TrovaGene (NYSE:TROV) lowered the target price from $13.00 to $12.00. At the time, this indicated a possible upside of 2.01%.
Having a price of $1.29, TrovaGene (NYSE:TROV) traded -25.71% lower on the day. The last stock close price is down -57.89% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. TROV has recorded a 50-day moving average of $1.99 and a 200-day moving average of $3.09. 2,446,641 shares of TROV traded, up from an avg. volume of 234,448
Recent Performance Chart
With a total market value of $0, TrovaGene has with a 52 week low of $1.25 and a 52 week high of $6.67 .
In addition to Piper Jaffray reporting its stock price target, a total of 5 analysts have released a report on TrovaGene. The 12-month price target is $6.30 with zero brokerages rating the company a strong buy, one brokerage rating the company a buy, four equity analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the stock a sell.
About TrovaGene (NYSE:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
The post Piper Jaffray downgraded TrovaGene (NYSE:TROV) from Neutral to Underweight in a report released today. appeared first on Octafinance.